Relmada continues to make progress with its emerging pain pipeline, completing a single ascending dose study and receiving clearance to commence a multiple ascending dose study for d-Methadone for neuropathic pain. It has also conducted a 1-for-5 reverse split in preparation for an uplisting to the NASDAQ by the end of 2015. We value the company at $591m or $54.68 per basic share, prior to any dilution from an estimated $110m funding requirement to profitability.
12 Oct 2015
Clinical progress and preparation for uplisting
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Clinical progress and preparation for uplisting
Relmada continues to make progress with its emerging pain pipeline, completing a single ascending dose study and receiving clearance to commence a multiple ascending dose study for d-Methadone for neuropathic pain. It has also conducted a 1-for-5 reverse split in preparation for an uplisting to the NASDAQ by the end of 2015. We value the company at $591m or $54.68 per basic share, prior to any dilution from an estimated $110m funding requirement to profitability.